Valery Krasnoperov
Chief Tech/Sci/R&D Officer bij HALO COLLECTIVE INC.
Profiel
Valery Krasnoperov is currently the Chief Scientific Officer at Halo Collective, Inc. Prior to this, he worked as the Director of Research & Development at VasGene Therapeutics, Inc. He also worked as a Research Scientist at New York University and The University of Nottingham.
Actieve functies van Valery Krasnoperov
| Bedrijven | Functie | Begin |
|---|---|---|
| HALO COLLECTIVE INC. | Chief Tech/Sci/R&D Officer | - |
Eerdere bekende functies van Valery Krasnoperov
| Bedrijven | Functie | Einde |
|---|---|---|
| New York University | Corporate Officer/Principal | - |
| The University of Nottingham | Corporate Officer/Principal | - |
VasGene Therapeutics, Inc.
 VasGene Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services VasGene Therapeutics, Inc. developed therapeutics based on vascular biology. Its products included target signal transduction pathways common to cancer cells and endothelial cells, resulting in anti-cancer agents with multiple modes of action and inhibition of tumor cell growth, anti-angiogenesis and prevention of tumor cell metastasis. The company was founded by Raymond A. Mirra Jr. and Parkash Gill in 1999 and was headquartered in Oak Park, CA. | Chief Tech/Sci/R&D Officer | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| HALO COLLECTIVE INC. | Process Industries |
| Bedrijven in privébezit | 1 |
|---|---|
VasGene Therapeutics, Inc.
VasGene Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services VasGene Therapeutics, Inc. developed therapeutics based on vascular biology. Its products included target signal transduction pathways common to cancer cells and endothelial cells, resulting in anti-cancer agents with multiple modes of action and inhibition of tumor cell growth, anti-angiogenesis and prevention of tumor cell metastasis. The company was founded by Raymond A. Mirra Jr. and Parkash Gill in 1999 and was headquartered in Oak Park, CA. | Commercial Services |
